Docoh
Loading...

BMY Bristol-Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Company profile

Ticker
BMY, BMYMP, CELG-RI
Exchange
Website
CEO
Giovanni Caforio
Employees
Incorporated
Location
Fiscal year end
SEC CIK
IRS number
220790350

BMY stock data

(
)

Calendar

28 Jul 21
4 Aug 21
31 Dec 21
Quarter (USD)
Jun 21 Mar 21 Dec 20 Sep 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 11.4B 11.4B 11.4B 11.4B 11.4B 11.4B
Cash burn (monthly) (positive/no burn) 747.08M (positive/no burn) 342.58M (positive/no burn) (positive/no burn)
Cash used (since last report) n/a 874.18M n/a 400.87M n/a n/a
Cash remaining n/a 10.52B n/a 11B n/a n/a
Runway (months of cash) n/a 14.1 n/a 32.1 n/a n/a

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
1 Aug 21 David V Elkins Common Stock, $0.10 par value Payment of exercise Dispose F No No 67.87 23,736 1.61M 109,699
1 Aug 21 David V Elkins Common Stock, $0.10 par value Option exercise Aquire M No No 0 46,403 0 133,435
1 Aug 21 David V Elkins RSU Common Stock, $0.10 par value Option exercise Dispose M No No 0 46,403 0 0
30 Jul 21 Autenried Paul von Common Stock, $0.10 par value Gift Aquire G Yes No 0 114,670.066 0 114,670.066
30 Jul 21 Autenried Paul von Common Stock, $0.10 par value Gift Dispose G No No 0 114,670.066 0 0
30 Jul 21 Autenried Paul von Common Stock, $0.10 par value Sell Dispose S No No 68.055 25,000 1.7M 114,670.066
30 Jul 21 Rupert Vessey Common Stock, $0.10 par value Sell Dispose S No No 68.08 140,653 9.58M 46,964
30 Jul 21 Rupert Vessey Common Stock, $0.10 par value Option exercise Aquire M No No 47.81 8,489 405.86K 187,617
30 Jul 21 Rupert Vessey Common Stock, $0.10 par value Option exercise Aquire M No No 44.7 8,489 379.46K 179,128
30 Jul 21 Rupert Vessey Common Stock, $0.10 par value Option exercise Aquire M No No 55.52 15,879 881.6K 170,639

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

71.8% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2292 2305 -0.6%
Opened positions 144 283 -49.1%
Closed positions 157 141 +11.3%
Increased positions 963 921 +4.6%
Reduced positions 912 847 +7.7%
13F shares
Current Prev Q Change
Total value 100.67B 102.7B -2.0%
Total shares 1.59B 1.66B -3.7%
Total puts 15.02M 20.66M -27.3%
Total calls 16.4M 24.15M -32.1%
Total put/call ratio 0.9 0.9 +7.1%
Largest owners
Shares Value Change
Vanguard 196.67M $12.42B -1.3%
BLK Blackrock 176.41M $11.14B +2.3%
STT State Street 90.95M $5.79B -3.4%
JPM JPMorgan Chase & Co. 76.04M $4.8B +5.1%
FMR 59.56M $3.76B +0.5%
Wellington Management 42.88M $2.71B -6.3%
Geode Capital Management 34.6M $2.18B +1.7%
BAC Bank Of America 33.09M $2.09B +2.4%
BRK.A Berkshire Hathaway 31.03M $1.96B -6.9%
AMP Ameriprise Financial 30.25M $1.91B +5.2%
Largest transactions
Shares Bought/sold Change
Norges Bank 0 -24.47M EXIT
Renaissance Technologies 6.97M -11.51M -62.3%
JHG Janus Henderson 15.69M -7.55M -32.5%
Loomis Sayles & Co L P 5.29M -6.18M -53.9%
BEN Franklin Resources 19.47M +5.17M +36.2%
GQG Partners 10.37K -4.48M -99.8%
BK Bank Of New York Mellon 22.46M -4.16M -15.6%
GS Goldman Sachs 13.68M +4.09M +42.6%
BLK Blackrock 176.41M +3.95M +2.3%
JPM JPMorgan Chase & Co. 76.04M +3.69M +5.1%

Financial report summary

?
Management Discussion
  • (a)    Other revenues include royalties and alliance-related revenues for products not sold by our regional commercial organizations.
  • (b)    Foreign exchange impacts were derived by applying the prior period average currency rates to the current period sales.
  • •U.S. revenues for the second quarter 2021 and year-to-date increased due to higher demand for Eliquis, our IO and new product portfolios and Revlimid. The second quarter 2020 was negatively impacted from sales channel inventory work downs and lower new patient starts due to the COVID-19 pandemic. Average U.S. net selling prices increased 1% year-to-date compared to the same period a year ago.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: Acceleron, Additionally, ago, alpha, Alzheimer, American, Amgen, backlog, binding, Biocon, bispecific, Century, cetuximab, China, conjugate, converting, decided, deficient, DFA, diligent, directly, dMMR, Eisai, eleven, endometrial, ESA, fluorouracil, folate, Francisco, fulfilled, HCM, hemoglobin, Hikma, histology, infusion, IO, joint, KCCQ, lack, Leiden, malignant, mCRC, mesothelioma, microtubule, minimum, mismatch, Molina, momentum, Mutual, network, neuroscience, NIH, OSS, ovarian, pleural, preclinical, Prothena, QUAZAR, Questionnaire, receipt, repair, Russia, salvage, SCCHN, shipment, specialty, strength, successor, Sweden, tentative, TIGIT, Torrent, trend, trustee, withdrew
Removed: administration, advisory, Assessment, biologic, Breckenridge, Cipla, diffuse, EMA, exhausted, favorable, MAA, mediastinal, MPM, newer, validated, variation